Lilly’s Q4 Growth Came From More Than Just Tirzepatide

 
• By Joseph Haas
  
Tirzepatide led a 45% revenue growth fourth quarter for Lilly (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Drug Pricing